Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AbbVie

Aflac

Franklin Resources

Cardinal Health

Hormel Foods

McKesson

Medtronic

NextEra Energy

Procter & Gamble

V.F.

Walgreens

S&P 500 dividend aristocrats possess pretty safe dividends. All 65 of them have paid out higher disbursements for at least 25 straight years. We decided to put together our Buy list for the top six to purchase right now.

The Dividend Aristocrat 6-Pack Buy List

Endo International

Teva Pharmaceutical

A California judge cleared four drugmakers of liability after a monthslong trial accusing the companies, including Johnson & Johnson JNJ, +0.09% and Endo International PLC ENDP, +8.94% , of causing widespread opioid addiction in the state.

The Wall Street Journal: Opioid makers cleared of liability in California lawsuit

A California judge on Monday said he would rule against several large counties who accused four drugmakers of fueling an opioid epidemic, saying they had failed at trial to prove their $50 billion case.

California judge rules for drugmakers in major opioid lawsuit

Costco

Johnson & Johnson and Costco Wholesale Corp have reached a tentative agreement to settle lawsuits over the presence of a cancer-causing substance in several recalled J&J sunscreen products.

J&J, Costco settle lawsuits over recalled sunscreen

Johnson & Johnson (NYSE: JNJ) says it has settled most of the lawsuits in the anti-psychotic drug Risperdal cases and has recorded $800 million in expenses in connection with the agreement. The medical devices and pharmaceuticals maker had almost 9000 cases over the Risperdal drug, and it accrued the entire legal expenses in the third quarter.

J&J Settles Anti-psychotic Drug Risperdal Lawsuits With $800 Million In Expenses

Johnson & Johnson said it has settled most of the lawsuits it faced by thousands of men who claimed its anti-psychotic drug Risperdal caused them to develop excessive breast tissue and disclosed that it recorded $800 million in expenses in connection with the agreement.

J&J settles most Risperdal lawsuits, with $800 million in expenses

The company is recovering from COVID induced headwinds and may develop a blockbuster vaccine to treat RSV.

Is Johnson & Johnson Stock A Buy, Sell, Or Hold?

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

The one-two punch of strong earnings and a guidance upgrade can generate bullishness around a stock.

2 Top Stocks That Raised Their Guidance After Strong Earnings Reports

Sientra

The FDA is restricting the sale and distribution of breast implants over concerns about the risks of the devices, limiting the products to healthcare providers and facilities that provide information using the "Patient Decision Checklist." Patients must be given a chance to initial and sign the checklist.

FDA Restricts Sale, Approves New Labeling Of Breast Implants

The vaccine maker is reportedly waiting for a green light from U.S. regulators before shipping out the doses.

Up To 50 Million J&J Vaccine Doses Reportedly Sitting Unused In Baltimore Manufacturing Plant

The healthcare giant delivered a solid performance in the third quarter.

What Investors Liked About Johnson & Johnson's Q3 Results

An estimated 30 million to 50 million doses of Johnson & Johnson's COVID-19 vaccine made early this year sits idle in Emergent BioSolutions Inc's plant in Baltimore awaiting a green light from U.S. regulators to ship, two sources familiar with the matter said.

Exclusive-Tens of millions of J&J COVID-19 shots sit at Baltimore factory -sources

Johnson & Johnson beat analysts' earnings expectations in the third quarter. But does the valuation make the Dividend King a buy?

Is This Steady Healthcare Stock a Buy?

MercadoLibre

These giant companies have the competitive advantage and consumer base to fight off inflation headwinds.

2 Top Stocks That Can Help Investors Crush Inflation

Bristol-Myers

Pfizer

3 Pharma Stocks You Can Buy and Hold Forever

Amgen

Fidelity MSCI Health Care ETF

Gilead Sciences

iShares U.S. Healthcare ETF

Eli Lilly

Merck

UnitedHealth Group

Vanguard Health Care ETF

Health Care Select Sector SPDR Fund

The healthcare sector is expected to witness substantial earnings growth of 17.5% in the third quarter.

Healthcare ETFs in Focus as Q3 Earnings Unfold

Johnson & Johnson (NYSE: JNJ) and its U.S.-based Janssen Pharmaceutical Companies have reached a $291.8 million settlement with the Texas state government that resolves its opioid-related claims made against the companies. What Happened: Johnson & Johnson will pay its settlement sum into the Qualified Settlement Fund, which represents Texas's allocation of the Global Prescription Opioid Litigation Settlement Agreement announced on July 23.

Johnson & Johnson Settles Opioid Claims In Texas For $291.8M

Colgate-Palmolive

Emerson Electric

Coca-Cola

With October almost over, many investors are looking ahead to Halloween, the holidays and the end of the year.

5 Dividend Aristocrats Stocks Have Raised Their Dividends for Almost 60 Years

Atea Pharmaceuticals

Novavax

Ghosts, goblins, ghouls? No, it's three vaccine stocks.

3 Top COVID Stocks -- Are They Tricks or Treats?

Johnson & Johnson historical performance is exceptional. The company offers a starting forward dividend yield of 2.6% and 59 consecutive years of dividend increases.

Johnson & Johnson: Currently Trading At Fair To Overvalued Territory

The company just got some good news from health authorities.

Does This News Make Johnson & Johnson a Buy?

Moderna

More than 47 million Pfizer vaccine recipients who received both shots at least six months ago became eligible for a booster Friday.

News for Johnson & Johnson Stock (JNJ)